HIV Drug "Lack Of Resistance" Claims Unlikely To Be Accepted By FDA
Executive Summary
FDA is unlikely to include "statements describing lack of resistance" in labeling for new antiretroviral drugs, FDA Medical Officer Jeffrey Murray, MD, told a Nov. 3 meeting of the Antiviral Drugs Advisory Committee.